Archive for October 2019

Patient focused care can only truly be supported with an empathetic perspective on patient experience. RWD  is typically utilised in reviewing clinical endpoints, however, it could be used for patient reported outcomes, and this is vital to a more holistic view of the disease area and its impact. Social media could be the gateway into…

Rapid and effective data generation increases value for the study sponsor. Larger groups allow for longitudinally tracking of patient cohorts and sub-population analyses Real world studies demonstrate real-world practices and behaviours. SVMPharma, driving the outcomes that matter with RWE studies leading to positive HTA submissions and value based outcomes. Why be limited with small study populations,…

A review on NICE’s HTA methodologies has been released, including review on quality of life measures NICE acknowledges the greater use of ‘data analytics and real-world evidence’ could play a part in how it might revise its methodologies. The aim is to support faster access to new technologies for patients Click here to read the source article…

Increased time-to-treatment-failure was revealed in a real world study on tofacitinib’s effectiveness The study allowed patients who wouldn’t have been considered for RCT inclusion to be analysed “This underscores the potential for real-world evidence studies to uncover new evidence of efficacy that might have been missed by the original controlled trials.” – Vivek Rudrapatna, University of California San Francisco…

Data can come from hospitals, patients, their family, government initiations, analytics companies, and a myriad of other potential partners For robustness, real-world data should come from several sources, allowing it to be translated into evidence to support other projects Coordinated co-operation is key to cover as many data sources as possible to fully utilise real-world…